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A B S T R A C T   
Parkinson’s disease (PD) is the most common form of neurodegenerative movement disorder, associated with 
profound loss of dopaminergic neurons from the basal ganglia. Though loss of dopaminergic neuron cell bodies 
from the substantia nigra pars compacta is a well-studied feature, atrophy and loss of their axons within the 
nigrostriatal tract is also emerging as an early event in disease progression. Genes that drive the Wallerian 
degeneration, like Sterile alpha and toll/interleukin-1 receptor motif containing (Sarm1), are excellent candi-
dates for driving this axon degeneration, given similarities in the morphology of axon degeneration after axot-
omy and in PD. In the present study we assessed whether Sarm1 contributes to loss of dopaminergic projections 
in mouse models of PD. In Sarm1 deficient mice, we observed a significant delay in the degeneration of severed 
dopaminergic axons distal to a 6-OHDA lesion of the medial forebrain bundle (MFB) in the nigrostriatal tract, and 
an accompanying rescue of morphological, biochemical and behavioural phenotypes. However, we observed no 
difference compared to controls when striatal terminals were lesioned with 6-OHDA to induce a dying back form 
of neurodegeneration. Likewise, when PD phenotypes were induced using AAV-induced alpha-synuclein over-
expression, we observed similar modest loss of dopaminergic terminals in Sarm1 knockouts and controls. Our 
data argues that axon degeneration after MFB lesion is Sarm1-dependent, but that other models for PD do not 
require Sarm1, or that Sarm1 acts with other redundant genetic pathways. This work adds to a growing body of 
evidence indicating Sarm1 contributes to some, but not all types of neurodegeneration, and supports the notion 
that while axon degeneration in many context appears morphologically similar, a diversity of axon degeneration 
programs exist.   
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acid; KO, Knock-out; LRRK2, Leucine-rich repeat kinase 2; MAPK, Mitogen-activated protein kinase; MFB, Medial forebrain bundle; ML, Medial lateral; NMNAT, 
Nicotinamide mononucleotide adenylyl-transferase; PBS, Phosphate buffered saline; PD, Parkinson’s disease; PINK1, Phosphatase and tensin homolog (PTEN) 
induced putative kinase 1; PRKN, Parkin RBR E3 ubiquitin protein ligase; ROS, Reactive Oxygen Species; SARM1, Sterile alpha and toll/interleukin-1 receptor (TIR) 
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1. Introduction 
Parkinson’s disease (PD) is the most common neurodegenerative 
movement disorder, with symptoms primarily caused by profound loss 
of dopaminergic neurons from the basal ganglia. Though loss of dopa-
minergic neuron cell bodies from the substantia nigra pars compacta 
(SNpc) is well described, atrophy and loss of their axons within the 
nigrostriatal tract occurs early in disease progression (Kurowska et al., 
2016). Suggestive of a retrograde mechanism of axon degeneration 
(Tagliaferro and Burke, 2016), neuritic aggregation of alpha-synuclein 
(Duda et al., 2002; Galvin et al., 1999), substantial reduction of dopa-
minergic terminals within the putamen (Kordower et al., 2013) and 
decreased levels of dopamine (Bernheimer et al., 1973; Cheng et al., 
2010; Lee et al., 2000; Riederer and Wuketich, 1976) all occur early in 
disease, often preceding destruction of cell bodies. Dopaminergic neu-
rons of the SNpc possess a vast, highly arborized axonal network that 
contacts many thousands of synaptic targets. The energetic and support 
demands of this critical neuronal compartment likely make the axons of 
DA neurons highly vulnerable to toxic insults underlying PD, with 
mitochondria dysfunction emerging as a likely contributing factor 
(Clark et al., 2006; Deng et al., 2008; Kitada et al., 1998; Valente et al., 
2004). 
Axon degeneration is emerging as a novel target for therapeutic 
intervention in the pathogenesis of PD and other neurodegenerative 
diseases. In recent years several genes have been identified as key 
molecules in driving Wallerian degeneration, a form of axon degeneration 
whereby axons severed from their cell body undergo rapid fragmenta-
tion and clearance (Waller, 1850). Wallerian degeneration is an active 
cellular process that can be suppressed by expression or suppression of 
signalling molecules. Suppression of Wallerian degeneration was first 
demonstrated in mice expressing the neomorphic gene Wallerian 
degeneration slow (WldS), composed of Nmnat1 and the N-terminal of 
ubiquitination factor E4B (Coleman et al., 1998; Lunn et al., 1989; Perry 
et al., 1990). Expression of WldS has been previously shown to suppress 
some forms of axon destruction in several models of neurodegeneration 
(Fischer et al., 2005; Meyer zu Horste et al., 2011; Mi et al., 2005; Wang 
et al., 2002; Wang et al., 2001) including toxin induced parkinsonism 
(Antenor-Dorsey and O’Malley, 2012; Cheng and Burke, 2010; Hasbani 
and O’Malley, 2006; Sajadi et al., 2004). Despite highlighting the exis-
tence of a programmed mechanism for axon destruction and showing 
promising disease modifying activity, mimicking the neomorphic action 
WldS has proven challenging. In an effort to identify endogenous genes 
driving programmed axon destruction, we previously conducted an 
unbiased forward genetic screen in Drosophila, identifying Sarm1 as a 
potent driver of severed axon destruction (Osterloh et al., 2012). Sarm1 
promotes axon destruction by actively hydrolysing NAD+, which has 
been proposed to deplete severed axons of this critical bioenergetic 
molecule (Essuman et al., 2017; Gerdts et al., 2015; Neukomm et al., 
2017; Summers et al., 2016). The neuron autonomous role for Sarm1 in 
Wallerian axon destruction is conserved in mammals (Gerdts et al., 
2013; Osterloh et al., 2012), making Sarm1 a promising therapeutic 
candidate for supressing axon destruction in neurodegenerative disease 
and injuries of the nervous system. In vivo experiments have however 
suggested Sarm1 has roles in some, but not all forms of axon degener-
ation. Sarm1 contributes to optic nerve crush models of glaucoma 
(Fernandes et al., 2018), traumatic brain injury (Henninger et al., 2016) 
and both chemotherapy- and metabolic dysfunction-induced peripheral 
neuropathy (Turkiew et al., 2017). In contrast Sarm1 does not appear to 
contribute to progressive degeneration of motor neurons seen in genetic 
models of amyotrophic lateral sclerosis (Peters et al., 2018; Sreedharan 
et al., 2015). 
In the present study we aimed to define if loss of Sarm1 can supress 
axon destruction in PD. Primary neuron tissue culture studies have 
demonstrated that Sarm1 contributes to the destruction of axons in 
response to toxins which mimic some of the mitochondrial dysfunction 
associated degenerative processes seen in PD (Summers et al., 2014). To 
determine whether Sarm1 contributes to in vivo dopaminergic axon 
destruction, we have tested whether Sarm1 drives the destruction of 
dopaminergic neurons in toxin and viral-mediated alpha-synuclein 
overexpression mouse models of parkinsonism. While Sarm1 knockout 
potently suppressed 6-OHDA lesioning of the medial forebrain bundle, 
loss of Sarm1 did not block axon dying back after 6-OHDA treatment of 
DA neuron terminals nor AAV-mediated alpha-synuclein overexpression 
models of PD. Our data support the notion that existing PD models 
induce genetically distinct programs of axon degeneration, some of 
which are Sarm1-dependent. 
2. Materials and methods 
2.1. Animals 
Sarm1 mice were obtained from Jackson laboratories (stock 
#018069) and maintained on a C57Bl6/J background. Experimental 
cohorts of wild type, Sarm1 heterozygous and Sarm1 homozygous null 
mice were generated through crossing of heterozygous animals. Mice 
were maintained on a 12 h light/dark cycle, with ad libitum access to 
standard mouse chow and water. Experiments were conducted by a re-
searchers blinded to genotype. All experimental protocols were 
approved by the University of Massachusetts Medical School Institu-
tional Animal Care and Use Committee. 
2.2. Surgery 
3-Month old male mice were anesthetized via inhalation of gaseous 
isoflurane, placed in a stereotaxic frame, the scalp shaved and cleaned, 
and a small anterior-posterior incision made to expose the skull. The 
injection site was identified and a small bore drilled using a dental drill 
bit. A Hamilton Neuros syringe fitted with a 33 gauge needle was used to 
deliver either 6-OHDA or AAV vector, delivered at a flow rate of 0.25 μl/ 
min using an automated injection pump and control unit (World Pre-
cision Instruments). Coordinates for unilateral lesioning of the medial 
forebrain bundle were AP − 1.2, ML +1.2, DV − 4.7, with a single de-
livery of 750 μl of 6.5 μg/μl 6-OHDA freebase dissolved in sterile saline 
containing 0.02% ascorbic acid. For unilateral lesioning of the striatum, 
two injections were given, at coordinates AP + 1.0, ML + 2.1, DV 2.9 
and AP +0.3, ML + 2.3, DV 2.9, with each injection site receiving 750 μl 
of 6.5 μg/μl 6-OHDA free base dissolved in sterile saline containing 
0.02% ascorbic acid. For delivery of AAV6-SNCA, vectors were unilat-
erally delivered to the substantia nigra pars compacta at coordinate AP 
− 2.8, ML 1.2, DV 3.8, delivering 1 μl 1.3 × 1013 vg/μl. Post-injection, 
the needle was left in place for 1 min to allow diffusion of injected so-
lution, followed by slow withdrawal of the needle. The skin of the scalp 
was then sutured, the animal treated with analgesic medication and 
allowed to recover in heated home cage. Post-surgery animals were 
housed separately. 
2.3. Amphetamine induced rotational behaviour 
At 7-days post-MFB lesion, mice were treated with 2.5 mg/kg 
amphetamine via intraperitoneal injection to induced rotational 
behaviour. Following the injection, mice were immediately placed in a 
glass beaker cage. Rotational behaviour was recorded over a 60-min test 
period and number of complete contralateral and ipsilateral rotations 
per 5-min bin counted. 
2.4. Alpha-Synuclein expression vectors 
A custom gene block was synthesised containing wild type human 
SNCA, a 5′ alpha subunit of Woodchuck hepatitis virus post- 
transcriptional regulatory element (WPRE) and SV40 polyA tail (Inte-
grated DNA Technologies). The SNCA construct was sub-cloned into an 
AAV backbone with human Synapsin 1 promotor mediated neuron 
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restricted gene expression (pTR-hSYN1-GFP, Gift from Miguel Sena- 
Esteves, University of Massachusetts Medical School (Vodicka et al., 
2016)). Packaging of the plasmids into AAV6 was performed by the 
University of Massachusetts Medical School virus core facility. 
2.5. Histology 
For harvesting of brains for histological analysis, mice were perfused 
with a pre-wash of PBS, followed by 4% paraformaldehyde dissolved in 
PBS. The brain was removed and post-fixed overnight in 4% para-
formaldehyde dissolved in PBS, followed by sinking in 25% sucrose and 
storage at 4C. 40 μm horizontal sections were collected using a Leica 
VT1200S vibratome and stored in an antifreeze solution (30% Glycerol, 
30% ethoxyethanol, 40% PBS) at − 20 ◦C. Free-floating sections were 
washed in PBS, then incubated in a blocking solution of 10% donkey 
serum (ThermoFisher) in PBS containing 0.4% TritonX100. Primary an-
tibodies were diluted in the same blocking solution and incubated 
overnight at 4C. Following washing with PBS, sections were treated with 
AlexaFluor secondary antibodies (ThermoFisher) for 3 h at room tem-
perature, followed by a final wash. Sections were mounted onto glass 
slides and allowed to dry overnight. Background auto-fluorescence was 
blocked by immersion of slides in a solution of 0.4% sudan black B in 
70% ethanol, followed by wash in 50% ethanol. Glass coverslips were 
applied using ImmunMount (Shandon). 
Images for analysis of dopaminergic terminal preservation following 
medial forebrain bundle lesion or treatment with SNCA vectors was 
conducted using a Zeiss AxioObserver three images were randomly 
collected at 40× magnification within the striata in a 1:6 section series, 
and distribution of tyrosine hydroxylase staining assessed using Cell-
Profiler (Broad institute (Lamprecht et al., 2007)). For dopaminergic 
neuron survival and alpha-synuclein expression quantification, cell 
bodies staining positive for tyrosine hydroxylase or alpha-synuclein in a 
1:3 (6-OHDA) or 1:6 (AAV-SNCA) section series, and quantified at 40×
magnification by a researcher blinded to genotype. For analysis of 
dopaminergic terminal preservation following striatal lesioning, images 
were collected using Innovative Imaging Innovations (3I) spinning-disc 
confocal microscope. Three images were randomly collected within the 
striata in a 1:6 section series, and volume of TH staining was assessed 
using Velocity 3D image analysis software (Perkin Elmer). Total sampled 
tyrosine hydroxylase staining or cell number per hemisphere were 
determined and presented as percentage relative to the unlesioned 
hemisphere. 
2.6. Antibodies 
The following antibodies were used for immunohistochemical 
staining; Rabbit anti-Tyrosine Hydroxylase, PelFreeze (P40101-150) 
1:1000; Mouse anti-Tyrosine Hydroxylase (TH-2), Sigma (T1299) 
1:1000; Rabbit anti-alpha Synuclein, Life Technologies (701085) 
1:1000; Rabbit anti-alpha Synuclein pSer129 (EP1536Y) AbCam 
(ab51253) 1:1000; Alexa Fluor 488 Donkey anti-Rabbit Life Technolo-
gies (A21206) 1:000 Alexa Fluor 546 Donkey anti-Rabbit Life Tech-
nologies (A10040) 1:1000; Alexa Fluor 488 Donkey anti-Mouse Life 
Technologies (A21202) 1:1000; Alexa Fluor 546 Donkey anti-Mouse Life 
Technologies (A10036) 1:1000. 
2.7. High performance liquid chromatography 
For harvesting tissues for HPLC analysis, animals were euthanized by 
overdose with CO2 followed by cervical dislocation. Brains dissected 
followed by microdissection of intact and lesioned striata which were 
frozen in liquid nitrogen and stored at − 80 ◦C. For HPLC analysis, in-
dividual striata were weighed, then homogenised in 150 mM phosphoric 
acid (Fisher) and 0.2 mM EDTA (Fisher). Sample were centrifuged at 
4 ◦C for 15 min at 17000 RCF. Supernatant was filtered by centrifuge 
tube filters (Costar Spin-X Centrifuge Tube Filter cellulose acetate filter, 
0.22 μm pore size) and stored at − 80 ◦C. Dopamine, DOPAC and HVA 
concentration were analysed using standard reverse-phase HPLC with 
electrochemical detection, as described previously (Chen et al., 2001; Xu 
et al., 2006). Dopamine and its metabolite concentrations were deter-
mined as picomoles per milligram of wet striatal tissue and presented as 
percentage of ipsilateral (lesioned) striata relative to the contralateral 
(non-lesioned) control striata. 
2.8. Statistics 
Statistical analysis was conducted using GraphPad Prism software. 
One-way or two-way analysis of variance (ANOVA) with Bonferroni 
post-hoc analysis, unpaired t-tests or linear regression were applied to 
data as appropriate, with all data displayed as mean ± standard error of 
mean (Mean ± SEM). 
2.9. Data availability 
All data presented in this study can be made available upon 
reasonable request. 
3. Results 
3.1. Sarm1 contributes to the destruction of chemically lesioned 
dopaminergic axons 
The mechanisms by which DA neurons degenerate in Parkinson’s 
disease and related disorders represent a potential target for therapeutic 
intervention that is poorly defined. To explore if Sarm1-mediated axon 
destruction contributes to the degeneration of DA neurons in PD, we set 
out to test the established models of dopaminergic neuron degeneration 
in mice either heterozygous (Het) or null (KO) for the gene. As Sarm1 
has been robustly demonstrated to play a critical role in the destruction 
of axons severed from their cell bodies (Gerdts et al., 2013; Osterloh 
et al., 2012; Peters et al., 2018), we first set out to establish whether it 
contributes to degeneration of dopaminergic axons following lesioning 
injuries. Neurons of the mouse nigrostriatal tract are an ideal target for 
in vivo study of DA neuron response to injury, with cell bodies of the 
SNpc projecting axons via the medial forebrain bundle (MFB) to distal 
synaptic targets located within the striatum, allowing axon injuries to be 
targeted to specific compartments of these cells. 
To induce severing injuries of dopaminergic axons from their asso-
ciated cell bodies we utilised a chemical lesioning approach, using ste-
reotactic injection of 6-hydroxydopamine (6-OHDA) into defined 
regions of the brain to trigger selective atrophy and destruction of DA 
and noradrenergic neurons. We first aimed to determine whether Wal-
lerian degeneration of DA axons and synapses separated from their cell 
bodies is promoted by Sarm1. Following lesioning injury we anticipated 
that distal DA axons would undergo typical Wallerian degeneration in 
mice expressing Sarm1 (ie WT and Sarm1 Het), with a rapid fragmen-
tation of severed axons followed by clearance of debris by surrounding 
glia. Unilateral injection of 6-OHDA in the MFB was used to lesions DA 
axons midway between the SNpc cell bodies and their synaptic terminals 
in the striatum, which allowed us to quantify both degeneration of ter-
minal and cells bodies, and compare this to the uninjured contralateral 
hemisphere (Fig. 1). Immunostaining for DA neuron specific tyrosine 
hydroxylase (TH) was used for detection and quantification of DA ter-
minals within the striata of mice 3- and 7- days after 6-OHDA lesioning 
of the MFB (Fig. 1A-C). As anticipated in WT animals, DA terminals in 
the uninjured control hemisphere were abundant, however at 3-days 
post-lesion TH staining was undetectable in the lesioned hemisphere, 
indicating profound degeneration and clearance of severed terminals. In 
striking contrast, we found significant preservation of DA terminals in 
the lesioned hemispheres of Sarm1 KO, and unexpectedly also in Sarm1 
Het mice, with over half the striatal DA terminals remaining. At day 7 
post-lesion, significant numbers of DA terminals remained in KO mice, 
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though they were absent in WT and negligible in Sarm1 heterozygous 
animals (Two-way ANOVA with Bonferroni multiple comparisons test; n 
= 4–8; Genotype F (2,33) = 22.74, p < 0.0001; Timepoint F (1,33) =
58.35, p < 0.0001; Interaction F (2, 33) = 13.05, p < 0.0001WT vs Het P 
< 0.0001; WT vs KO p < 0.0001). 
Following 6-OHDA lesioning DA cell bodies of the SNpc and to a 
lesser extent the adjacent ventral tegmental area (VTA) are also lost. To 
assess whether Sarm1 contributes to the death of DA neurons we 
quantified the number of cell bodies present in the lesioned and control 
SNpc and VTA proximal to the 6-OHDA lesioning injury (Fig. 1D). To 
allow for sufficient time to induce neuronal cell body degeneration an-
imals were assessed at 14-days post-lesion. We observed comparable 
rates of cell death of DA cell bodies in the SNpc (Fig. 1E) and ventral 
tegmental area (Fig. 1F) in control and Sarm1 mutant mice 14-days post- 
lesion. 
Having demonstrated Sarm1 contributes to the physical destruction 
of DA terminals in mice, we next assessed whether remaining synapses 
retained the ability to maintain stored reserves of vesicular DA or its 
metabolites. Using high performance liquid chromatography (HPLC) we 
quantified levels of striatal DA, DOPAC and HVA at 3-, 7- and 14-days 
post 6-OHDA lesion relative to the intact contralateral hemisphere 
(Fig. 2). Whilst stored DA was absent in lesioned hemisphere of wild 
type mice, (Fig. 2A) significant protection was observed in Sarm1 KO 
animals in both 3- and 7-day time points post-lesion, with a non- 
significant trend also observed in heterozygotes (Two-way ANOVA 
with Bonferroni multiple comparisons test, n = 3–4; Genotype F (2, 25) 
= 19.57 P < 0.0001; Timepoint F (2, 25) = 22.03, P < 0.0001; Inter-
action F (4, 25) = 6.405, P = 0.0011, 3-days WT vs KO p < 0.0001, 7- 
days WT vs KO p < 0.05). DOPAC was detected in the lesioned hemi-
sphere of all animals at 3-days (Fig. 2B), with a significant elevation seen 
in heterozygous animals relative to the intact hemisphere (Two-way 
ANOVA with Bonferroni multiple comparisons test, n = 3–4; Genotype F 
Fig. 1. Protection of lesioned dopaminergic axons in Sarm1 null mice. (A) Schematic showing MFB lesioning model indicating target region for 6-OHDA injection. 
(B) Tyrosine hydroxylase (TH) staining of DA terminals in the striatum of Sarm1 null mice, 3 and 7 days post 6-OHDA lesion of the MFB. (C) Quantification of striatal 
TH density (n = 4–8, 2-way ANOVA, Bonferonni post-hoc test *** = p < 0.001). (D) Horizontal section containing SNpc DA neuron cell bodies immunostained for TH 
14 days post MFB lesion. (D,E) Quantification of DA neuron number in the SNpc (E) and VTA (F) 14 days post MFB, expressed as percentage of dopaminergic neuron 
cell bodies in the lesioned hemisphere relative to the uninjected contralateral hemisphere (n = 4–5, one-way ANOVA). Scale bars A = 30 μm, C = 50 μm. 
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(2, 25) = 3.774, P = 0.0370; Timepoint F (2, 25) = 13.78, P < 0.0001; 3- 
days WT vs Het p < 0.05). DOPAC was not preserved at 7-days post- 
lesion in either Het and KO animals. Significant protection of HVA 
(Fig. 2C) levels was seen in lesioned Sarm1 KO striata at both 3- and 7- 
days post-lesion, with a non-significant trend toward protection also 
observed in Hets (Genotype F (2, 25) = 9.594, P = 0.0008; Timepoint F 
(2, 25) = 16.07, P < 0.0001; 3-days WT vs KO p < 0.05, 7-days WT vs KO 
p < 0.05). No significant protection of DA nor its metabolites was 
detected at 14-days post-lesion in any of the experimental cohorts. 
The presence of DA in lesioned striata of Sarm1 mutant mice suggests 
that blocking Wallerian degeneration allows severed terminals to retain 
at least the functional capacity to store neurotransmitters. We next set 
out to test whether these severed terminals retained the ability to signal 
to post-synaptic neurons of the striata, utilising d-amphetamine 
(dAMPH), which potently stimulates the release of dopamine and in-
duces asymmetric rotational behaviour in mice harbouring unilateral 6- 
OHDA lesions. Typically, after clearance of lesioned DA terminals, wild 
type mice will undergo rotational behaviour ipsilateral of the lesion (i.e. 
in the direction of the lesioned hemisphere). Indeed, at 7-days post-MFB 
lesion we found control WT mice, where nigrostriatal terminals and DA 
are absent, underwent sustained ipsilateral rotational behaviour 
following stimulation with dAMPH (Fig. 3). However, in striking 
contrast, following dAMPH stimulation Sarm1 KO, and to a comparable 
levels in Sarm1 Het mice, demonstrated sustained rotations in the di-
rection contralateral to the lesion (Two-way ANOVA with Bonferroni 
multiple comparisons test, n = 4–6; Genotype F (2, 143) = 58.76 P <
0.0001; Time F (11, 143) = 1.731 P = 0.0722; Interaction F (22, 143) =
0.8549 P = 0.6530; post-hoc annotation Fig. 3). This non-typical rota-
tional behaviour is in agreement with a previous report of WldS mice 
following MFB lesioning, where dopaminergic terminals were also found 
to be preserved (Sajadi et al., 2004). The pronounced contralateral ro-
tations observed in both WldS transgenic and Sarm1 mutant mice sug-
gests that following severing injuries rather than remaining inactive, 
nigrostriatal terminals may continue to synthesise and accumulate 
dopamine, which stimulated through non-physiological dAMPH- 
induced DA release elicits an enhanced response in the contralateral 
direction. 
3.2. Sarm1 does not contribute to retrograde degeneration of 
dopaminergic axons 
Lesioning of the MFB demonstrated that the synaptic terminals of DA 
neurons lacking Sarm1 are both morphologically and functionally pro-
tected from Wallerian degeneration following severing injuries. 
Breakage of the axon along its length, degeneration and synaptic loss in 
DA neuron populations may occur during neurodegeneration in PD, 
however transecting injuries are not likely the major driver of neuro-
degeneration in PD and related “dying back” disorders. Indeed, evidence 
from PD patients suggests DA neurons undergo such a dying back pro-
cess, where degeneration initiates at distal synapses and progresses to 
the cell bodies (Tagliaferro and Burke, 2016). To determine whether 
Sarm1 contributes to axonal dying back of SNpc DA neurons more 
typical of PD, we conducted unilateral 6-OHDA lesioning of DA neurites 
and synaptic terminals within the striatum (Fig. 4). TH immunostaining 
for DA axon terminals within the lesioned striata of both WT control and 
Sarm1 KO animals detected only the sparse presence of fragmented DA 
terminals, with quantification revealing no significant protection in 
mice lacking Sarm1 (Fig. 4A, B). As 6-OHDA lesioning is an acute 
chemical insult, it is feasible that any contribution of Sarm1 in die back 
degeneration of distal portions of these DA axons within the striatum 
may be masked by the severity of the injury. To assess whether Sarm1 
Fig. 2. Significant presence of dopamine and its metabolites in the striata of 
MFB 6-OHDA lesioned Sarm1 knock out mice. High-Performance Liquid 
Chromatography (HPLC) quantification of striatal (A) dopamine, (B) DOPAC 
and (C) HVA at 3-, 7- and 14-days post 6-OHDA lesion of the MFB in WT and 
Sarm1 knock out mice (mean ± SEM, n = 3–4, 2-way ANOVA, Bonferonni post- 
hoc, ** p < 0.01, *** p < 0.001). 
Fig. 3. Amphetamine induced rotational behaviour of mice lacking Sarm1 
shows preservation of dopamine release function. Rotational behaviour of WT 
and Sarm1 KO mice administered with 2.5 mg/kg dAMPH 7 days post MFB 6- 
OHDA, recorded over a 60 min test period in 5-min bins. (Mean ± SEM, n =
4–6, 2-way ANOVA, Bonferroni post-hoc, * p < 0.05, ** p < 0.01, *** p <
0.001, # = WT vs Het, * = WT vs KO, Het vs KO showed no significant 
differences). 
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contributes to die back of these axons beyond their striatal portion, we 
next examined DA axons within the MFB of WT control and Sarm1 KO 
animals 3-days post-lesion (Fig. 4D). In both control and Sarm1 KO 
animals, a consistent pattern of DA axon degeneration was evident 
within the MFB of the lesioned hemisphere. In both genotypes swollen 
and dystrophic neurites were observed in distal and medial axon por-
tions but not proximal regions adjacent to SNpc cell bodies. Taken 
together this data suggests striatal 6-OHDA lesioning triggers a process 
of DA axon die back that progresses beyond the striatum, however did 
not suggest a contribution for Sarm1 in this degeneration. 
Though 6-OHDA lesioning mimics aspects of parkinsonian neuro-
degeneration by selectively injuring dopaminergic neurons, it is a 
rapidly destructive, acute insult that does not recapitulate the more 
slowly progressive degeneration seen in patients. In an effort to assess 
the role of Sarm1 in a more physiological, slowly progressing model of 
PD, we next turned to adeno-associated virus (AAV) mediated expres-
sion of SNCA, an approach which has previously been utilised to induce 
Parkinsonian degeneration of DA neurons (Decressac et al., 2012), with 
increased expression of SNCA likely representing a more physiologically 
relevant (Chartier-Harlin et al., 2004; Ibáñez et al., 2004; Singleton 
et al., 2003) model of axon degeneration. We generated adeno- 
associated viral (AAV6) vectors to drive expression of human wild 
type SNCA by the neuron specific human synapsin 1 promoter. AAV6- 
SNCA were injected unilaterally into the SNpc of 10–12 week old WT, 
Sarm1 Het and KO mice with the non-injected contralateral hemisphere 
serving as an internal control (Fig. 5). Immunostaining for alpha- 
synuclein revealed widespread expression throughout SNpc neurons 
and their striatal terminals in the brains of injected mice 12-weeks post- 
surgery, with evidence of histopathological hallmarks of synuclein 
associated neuron damage including swollen neurites containing alpha 
synuclein (Fig. 5A) and its disease-associated (Fujiwara et al., 2002) 
Ser129 phosphorylated species (Fig. 5B). 
To assess if our model of alpha synuclein overexpression impacted 
axon survival, experimental cohorts were aged for 6-months post- 
surgery, followed by collection of brains for immunohistological 
assessment. To define if increased expression of alpha synuclein induced 
axonal die back we immunostained striata for presence of TH positive 
neurites, observing a notable reduction in dopaminergic neurites pre-
sent in the striata of injected hemisphere of WT control and Sarm1 
mutant mice (Fig. 5D, E). Quantification and statistical analysis of TH 
immunostaining indeed revealed a significant effect of treatment with 
AAV6-SNCA, however no significant difference was observed among 
controls and Sarm1 knockouts, indicating Sarm1 indicating that loss of 
Sarm1 alone is not sufficient to block alpha-synuclein mediated degen-
eration of dopaminergic terminals (Two-way ANOVA with Bonferroni 
multiple comparisons test, n = 3–8; Treatment F (1, 33) = 29.61, P <
0.0001; Genotype F (2, 33) = 0.2364, P = 0.7908; Interaction F (2, 33) 
= 0.6026 P = 0.5533). Neurodegeneration in PD is perhaps best defined 
Fig. 4. Sarm1 does not contribute to retrograde 
degeneration of 6-OHDA lesioned dopaminergic 
axons. (A) TH staining of the striatum of WT mouse 3 
days post striatal lesion TH staining was significantly 
reduced with only degenerating portions of axons 
remaining. (B) Quantification of TH staining of 3 day 
post-lesioned WT and Sarm1 KO mice revealed no 
preservation of terminals relative to the unlesioned 
contralateral control hemisphere (mean ± SEM, n =
3, unpaired t-test, p = ns). (C) Schematic showing 
striatal lesioning model indicating target region for 6- 
OHDA injection. (D) Micrographs showing TH im-
munostaining of the distal, medial and proximal 
portions of the MFB (relative to SNpc) 3 days post 
lesioning of the striatum. Significant degeneration is 
seen in the distal and medial portions in both WT and 
Sarm1 KO mice indicated by the presence of large 
swollen, dystrophic axons, though the proximal re-
gions are more intact. Scale bars A = 30 μm, D = 60 
μm).   
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by the dramatic loss of DA neuron cell bodies in the SNpc. To assess 
whether Sarm1 contributes to this degeneration we quantified SNpc DA 
cell bodies in WT and Sarm1 mutant mice at the 6-month post-infection 
timepoint. Quantification revealed a modest loss of DA neuron cell 
bodies in the SNCA expressing hemisphere of all genetic backgrounds, 
indicated by a significant effect of treatment group, however post-hoc 
analysis failed to detect any significant difference in cell count between 
AAV6-SNCA and uninjected control con hemispheres. No significant 
Fig. 5. Sarm1 does not contribute to alpha synuclein-induced degeneration of dopaminergic axons. (A) Human alpha-synuclein and (B) Ser129-phosophylated 
species were detected within beaded DA axons in the striatum of 12-week old injected wild type mice. (C) Schematic showing AAV6-SNCA model targeting 
dopaminergic neurons of the SNpc. (D) TH staining of DA axons in contralateral (uninjected hemisphere) and ipsilateral striatum (injected hemisphere) of WT and 
Sarm1 null mice 6-months post-injection. (E) Quantification of striatal TH staining density in AAV6-SNCA injected mice compared to uninjected control mice (mean 
± SEM two-way ANOVA, * p < 0.05). (F) Quantification of SNpc DA cell bodies relative to the contralateral hemisphere of AAV-SNCA injected groups compared to 
uninjected animals (mean ± SEM, two-way ANOVA, n = 3–8). (G) Striatal TH density correlated with number of alpha-synuclein positive neurons in the transfected 
SNpc (Linear regression; slope p = ns, intercept p = ns). Scale bar A,B = 20 μm; C = 60 μm. 
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differences were detected between WT or Sarm1 mutant genotypes, 
again indicating that loss of Sarm1 alone does not block degeneration of 
DA cell bodies (Fig. 5F, Two-way ANOVA with Bonferroni multiple 
comparisons test, n = 3–8; Treatment F (1,31) = 19.84, P = 0.0001; 
Genotype F (2,31) = 0.6554, P = 0.5263; Interaction F (2, 31) = 0.5699, 
P = 0.5714). To account for variability in transfection efficiency which 
may obscure more subtle changes in DA neuron degeneration, we finally 
quantified the number of SNCA transfected DA cell bodies and corre-
lated this with loss of TH positive terminals for individual mice (Fig. 5G), 
however we again failed to detect any significant differences between 
WT and Sarm1 mutant cohorts. Taken together these data suggest that 
whilst Sarm1-mediated axon destruction drives the Wallerian degener-
ation of DA axons severed from their cell bodies following lesioning 
injuries, it is not the primary driver of PD relevant alpha-synuclein 
induced degeneration of SNpc dopaminergic terminals and cell bodies, 
though it remains feasible it may contribute in parallel to other path-
ways for axon destruction. 
4. Discussion 
Axon degeneration can be triggered through a variety of pathogenic 
insults, ranging from physical injury, autoimmune damage and disease- 
associated neurodegeneration such as that seen in Parkinson’s disease. 
Whilst it was initially speculated that axon degeneration in development 
and many diseases may be mechanistically related (Raff et al., 2002), 
emerging experimental evidence is increasingly supporting the opposite 
notion—that different forms of injury or trauma activate diverse genetic 
pathways driving the destruction of axons. Indeed, our study further 
supports the notion of diverse genetic mechanisms of axon destruction 
being engaged even in the very same neurons when severed by 6-OHDA 
compared to application at DA terminals. Reduced expression of Sarm1 
potently delayed the degeneration of dopaminergic axons distal to a 
chemical lesion in the MFB, which were remarkably capable of main-
taining the ability to both store and release dopamine several days post 
injury. However, retrograde die back destruction of the same DA neuron 
axons progressed unhindered following chemical lesioning of terminals 
in animals lacking Sarm1. Similarly, loss of Sarm1 did not alter loss of 
terminals in our model of PD-associated alpha-synuclein overexpression. 
Thus despite being essential for efficient destruction of lesioned dopa-
minergic axons, Sarm1 alone does not appear to drive the process of 
axon die back or synuclein overexpression induced damage to these 
neurons. This does not exclude a role for Sarm1—for instance, Sarm1 
could be working with other redundant genetic pathways to drive 
destruction in the die back models, which remain to identified. Never-
theless, our alpha synuclein data strongly suggests that classical, Sarm1- 
mediated Wallerian degeneration is not the major driving force 
contributing to axon destruction in PD and associated 
synucleinopathies. 
PD is a genetically heterogenous condition, with SNCA mutations 
accounting only for a small fraction of familial cases (Chartier-Harlin 
et al., 2004; Ibáñez et al., 2004; Polymeropoulos et al., 1997; Singleton 
et al., 2003). Our rodent model of synuclein overexpression provides 
further support to the notion that axons undergo a process of retrograde 
destruction in PD, with loss of striatal terminals preceding any detect-
able loss of neuron cell bodies in the SNpc. As more PD associated genes 
are identified, we will gain a greater depth of understanding of the 
cellular processes driving disease onset and progression. In the various 
subtypes of familial PD, and even more so in the more common idio-
pathic form of disease, neither the precise pathogenic events nor the 
processes by which axons degenerate are fully understood. For example, 
Sarm1 has previously been shown to protect in vitro rodent sensory 
neurons from mitochondria-depolarisation induced death (Summers 
et al., 2014). As mutations in key mitophagy genes PINK1 (Kitada et al., 
1998; Matsumine et al., 1997) and PRKN are causative of PD (Larsen 
et al., 2018), it is feasible Sarm1 may contribute to the specific forms of 
axon destruction induced by mitochondria dysfunction. Other PD- 
associated genes including LRRK2 (Paisán-Ruíz et al., 2004; Zimprich 
et al., 2004) and GBA (Sidransky et al., 2009) have been linked to 
dysfunction of the endo-lysosomal system, for which roles for Wallerian 
degeneration associated genes have yet to be explored. In order to gain a 
better understanding of if and when Sarm1 inactivation may be of 
therapeutic benefit in PD, it will be essential to explore a broad range of 
disease-associated models of DA axon destruction. 
In parallel to the continued identification of genes associated with 
PD, the repertoire found to regulate Wallerian degeneration is also 
expanding (Coleman et al., 1998; Farley et al., 2018; Mack et al., 2001; 
Miller et al., 2009; Neukomm et al., 2017; Osterloh et al., 2012; Xiong 
et al., 2012; Yang et al., 2015). Whilst loss of Sarm1 potently inhibits 
destruction of severed axons but has varied effect in models of neuro-
degeneration (Fernandes et al., 2018; Peters et al., 2018; Turkiew et al., 
2017), the role of other axon death genes including Highwire, Axundead, 
Nmnat and the MAPK signalling cascade remain unclear. Functional 
redundancy may exist in axon degeneration pathways, and its blockade 
may require inhibition of multiple pathways simultaneously to save 
axons. Further characterization of Wallerian degeneration signalling 
pathways, and the mechanisms of programmed axon destruction in 
disease will be essential to bridge this gap in our understanding and may 
help identify meaningful therapeutic approaches to neurodegenerative 
disease. 
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